Overview

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study

Status:
Active, not recruiting

Trial end date:
2021-03-01

Target enrollment:

Participant gender:

Summary

The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Español de Tumores Huérfanos e Infrecuentes

Collaborators:

Apices Soluciones S.L.
Astellas Pharma Inc